Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization
Wen-Chi Su,Zan-Yu Chen,Young-Sheng Chang,King-Song Jeng,Uyen Nguyen Phuong Le,Yu-Chi Chou,Li-Lan Kuo,Ivonne Melano,Jesse,Wei-Jan Wang,Ying-Chyi Song,Sin-Rong Li,Mien-Chie Hung,Michael M C Lai,Cheng-Wen Lin,Michael M.C. Lai
DOI: https://doi.org/10.1016/j.antiviral.2023.105744
IF: 7.6
2023-11-09
Antiviral Research
Abstract:Working with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is restricted to biosafety level III (BSL-3) laboratory. The study used a trans-complementation system consisting of virus-like particles (VLPs) and DNA-launched replicons to generate SARS-CoV-2 single-round infectious particles (SRIPs) with variant-specific spike (S) proteins. S gene of Wuhan-Hu-1 strain (S WH1 ) or Omicron BA.1 variant (S BA.1 ), along with the envelope (E) and membrane (M) genes, were cloned into a tricistronic vector, co-expressed in the cells to produce variant-specific S-VLPs. Additionally, the replicon of the WH1-like strain without S, E, M and accessory genes, was engineered under the control by a CMV promoter to produce self-replicating RNAs within VLP-producing cells, led to create S WH1 - and S BA.1 -based SARS-CoV-2 SRIPs. The S BA.1 -based SRIP showed lower virus yield, replication, N protein expression, fusogenicity, and infectivity compared to S WH1 -based SRIPs. S BA.1 -based SRIP also exhibited intermediate resistance to neutralizing antibodies produced by S WH1 -based vaccines, but were effective at infecting cells with low ACE2 expression. Importantly, both S-based SRIPs responded similarly to remdesivir and GC376, with EC50 values ranging from 0.17 to 1.46 μM, respectively. The study demonstrated that this trans-complementation system is a reliable and efficient tool for generating SARS-CoV-2 SRIPs with variant-specific S proteins. SARS-CoV-2 SRIPs, mimicking authentic live viruses, facilitate comprehensive analysis of variant-specific virological characteristics, including antibody neutralization, and drug sensitivity in non-BSL-3 laboratories.
pharmacology & pharmacy,virology